How do we fix high list prices? The Trump administration remains convinced that the answer lies in pointing the finger at the rebating system, and instituting changes to it. When Pfizer recently announced an increase in list prices for 10% of their drugs (41 in all), Health and Human Services Secretary Eric Hargan used it as evidence that changing the rebate system is the pathway to lowering drug costs overall. Read more about Hargan’s comments on the matter, made during December’s FDA/CMS Summit in Washington, in this essential Pink Sheet article.